Interaction of radiation therapy with molecular targeted agents - Wikidata - wikimedia - TriplyDB

Interaction of radiation therapy with molecular targeted agents

Interaction of radiation therapy with molecular targeted agents

http://www.wikidata.org/entity/Q34124285

about

Cellular Pathways in Response to Ionizing Radiation and Their Targetability for Tumor Radiosensitization External beam re-irradiation, combination chemoradiotherapy, and particle therapy for the treatment of recurrent glioblastoma Multimodality treatment of brain metastases from renal cell carcinoma in the era of targeted therapy Molecular radiobiology: the state of the art Personalized radiotherapy: concepts, biomarkers and trial design Evaluation of connectivity map-discovered celastrol as a radiosensitizing agent in a murine lung carcinoma model: Feasibility study of diffusion-weighted magnetic resonance imaging.Valproic acid enhances the efficacy of radiation therapy by protecting normal hippocampal neurons and sensitizing malignant glioblastoma cells.STAT3-survivin signaling mediates a poor response to radiotherapy in HER2-positive breast cancers.Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize.The Rationale for Targeted Therapies and Stereotactic Radiosurgery in the Treatment of Brain Metastases.Opportunities and challenges of radiotherapy for treating cancer.EGFR targeted therapies and radiation: Optimizing efficacy by appropriate drug scheduling and patient selection.Inhibition of pH regulation as a therapeutic strategy in hypoxic human breast cancer cells.Targeting pathways mediating resistance to anti-EGFR therapy in squamous cell carcinoma of the head and neck.Radiation oncology: a snapshot in time, 2014.MK-8776, a novel chk1 kinase inhibitor, radiosensitizes p53-defective human tumor cells.Enhancing the efficacy of radiation therapy: premises, promises, and practicality.Comprehensive molecular tumor profiling in radiation oncology: How it could be used for precision medicine.Blood-brain barrier crossing and breakthroughs in glioblastoma therapy.Stereotactic body radiation therapy as a derivative of stereotactic radiosurgery: clinically independent but with enduring common themes.Tumor radiosensitization by gene therapy against endoglin.Exploiting radiation-induced signaling to increase the susceptibility of resistant cancer cells to targeted drugs: AKT and mTOR inhibitors as an example.Dual blockade of PI3K and MEK in combination with radiation in head and neck cancer.

P2860

Q26771165-28A508ED-80D5-469A-BB12-D20AFF629047 Q28067135-4F812B34-0483-4B1D-8FE0-D36850BC1F3D Q28077050-26E6AD7F-DF90-437D-96EB-15DF1F2284C3 Q34124274-2F4EAF84-376D-45F8-BEC9-71FAF9D17FAC Q36235704-0FC4BE4E-F3B4-4097-BC54-F704C3B197E0 Q36381094-1FFD24B3-A3CE-4850-9B8E-C4942C0C69FB Q36544286-D5AAB16B-56A7-47AA-95F8-03E7BF2AE32B Q36916416-C5AAA908-51CE-4260-B050-6461F251113D Q37329842-C56F6D2C-5E5F-460A-82D6-2DE14C16DD02 Q38289478-3B11639E-399C-487D-A61B-2348C693853D Q38539957-2E1EF59C-ACD0-4646-90CD-84906B769AC5 Q38552978-C28C8850-E4B9-4AC3-A600-3F5A0D4AD28C Q38704678-A5776BCE-5857-4461-8CE7-96261740D295 Q38892486-67E0389D-7251-4F94-A611-ECFB133D500D Q41831535-7AEED8D4-E19D-443F-B832-920841DE3169 Q42317541-BDA97929-CC91-4B15-9370-61A67E926905 Q42545565-C00EF386-7633-440D-96CF-719A7A34094E Q42587971-937A41C1-BF24-4C5D-A229-C64F0404A286 Q42770381-88D7D69B-3151-41DC-83D7-CDFC43F13242 Q42857993-1C135696-D66A-4C6E-BC66-358377263B57 Q45886138-D11BEFC6-CE45-4CD9-B46E-9311B7EE7FF0 Q47960830-4C943EEF-045F-4CFC-9AA3-B37BA6E15C27 Q55689566-27014E16-3DF5-43F1-B2C7-7AC2C4C08B8E

P2860

Interaction of radiation therapy with molecular targeted agents

http://www.wikidata.org/entity/Q34124285

description

2014 nî lūn-bûn

@nan

2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Interaction of radiation therapy with molecular targeted agents

@ast

Interaction of radiation therapy with molecular targeted agents

@en

Interaction of radiation therapy with molecular targeted agents

@nl

type

label

Interaction of radiation therapy with molecular targeted agents

@ast

Interaction of radiation therapy with molecular targeted agents

@en

Interaction of radiation therapy with molecular targeted agents

@nl

prefLabel

Interaction of radiation therapy with molecular targeted agents

@ast

Interaction of radiation therapy with molecular targeted agents

@en

Interaction of radiation therapy with molecular targeted agents

@nl

P1433

Q34124285-3D4D365C-F8A5-474F-BA3D-2796C830A088

P1476

Q34124285-83851CC9-C073-4366-8DA2-ACE0FABAAE95

P2093

Q34124285-FB630245-D6F1-48FF-8BFF-A1F8A0CB227E

P2860

Q34124285-0721F970-7D8A-49BC-A0E8-62937C503034

Q34124285-0E65CB04-19EC-48DB-96ED-7A670E2BA1DE

Q34124285-144CE111-7CB2-4755-BB97-F4AB3D4AEFE0

Q34124285-18726291-CC98-459E-BB5A-A944F7E4CCD9

Q34124285-1A2FE7A1-4BF3-4B56-82CF-B9157D0E9FDD

Q34124285-36A1B5FB-8D1B-4639-9BFC-26344521BE64

Q34124285-411812BB-EB0A-4B33-9B4C-BCE13B591116

Q34124285-480A055B-D0DC-4E5B-A829-4526B68B294E

Q34124285-525F156E-65D5-4BA4-ABFC-48EB0810BCEE

Q34124285-5A277669-D276-43A4-B25A-4D6CF5E850D8

P304

Q34124285-52B65FE1-0566-4B62-8D1B-5D626C1B0187

P31

Q34124285-EAEFF979-0CC0-4058-BD53-65FC8945F5C4

P356

Q34124285-CC0087A0-31B2-4970-A463-BFF40B375993

P407

Q34124285-68F9685D-3D38-4AB3-B189-3D049861F052

P433

Q34124285-C9ACCE0F-263A-476E-AC27-3DDFDE1E57FC

P478

Q34124285-306D8759-5851-43A8-95A4-4148CD0A62B0

P50

Q34124285-71FEAB25-7ACE-4639-8B96-17218D5ED3F5

P577

Q34124285-C23C9D3A-3881-46BF-9FA8-DD386048E52F

P698

Q34124285-A6459985-494D-4FF1-9346-12F650981DEC

P921

Q34124285-CC751C2A-3527-4717-9067-FE1922D4D7BA

P932

Q34124285-9B96E5B6-D252-421F-8B76-506DCCE2FE44

P356

JCO.2014.55.1366

P1433

Journal of Clinical Oncology

P1476

Interaction of radiation therapy with molecular targeted agents

@en

P2093

Paul M Harari

http://www.w3.org/2001/XMLSchema#string

P2860

Combining radiotherapy and cancer immunotherapy: a paradigm shift

Cetuximab for the treatment of colorectal cancer.

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411

Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck.

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.

Combination of temsirolimus (CCI-779) with chemoradiation in newly diagnosed glioblastoma multiforme (GBM) (NCCTG trial N027D) is associated with increased infectious risks

Grand rounds at the National Institutes of Health: HDAC inhibitors as radiation modifiers, from bench to clinic

P304

2886-2893

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2014.55.1366

http://www.w3.org/2001/XMLSchema#string

P407

P433

26

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P50

Zachary S Morris

P577

2014-08-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25113770

http://www.w3.org/2001/XMLSchema#string

P921

radiation therapy

P932

4152717

http://www.w3.org/2001/XMLSchema#string